Timóteo Rodolfo Pessato, Micheli Douglas Cobo, Teodoro Reginaldo Botelho, Freire Marlene, Bertoncello Dernival, Murta Eddie Fernando Candido, Tavares-Murta Beatriz Martins
Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.
Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.
Rev Bras Reumatol Engl Ed. 2016 Nov-Dec;56(6):497-503. doi: 10.1016/j.rbre.2016.02.009. Epub 2016 Mar 11.
To characterize the inflammatory profiles of patients with systemic lupus erythematosus receiving standard treatment compared to healthy controls.
Peripheral venous blood was collected from systemic lupus erythematosus patients (n=14) and controls (n=18) at enrollment. Blood samples were used for quantification, by flow cytometry, of CD11b (integrin) and Chemokine receptor CXCR2 expression surface antigen in neutrophils and lymphocytes, while cytokines were assayed in serum samples. Purified neutrophils were assayed by their ability to phagocytize human plasma-opsonized zymosan.
Patients had a median (interquartile range) disease activity index of 1.0 (0-2.0) characteristic of patients in remission. Interleukin-6 and interleukin-10 serum concentrations were significantly higher in the patient group compared to controls and the phagocytic index of circulating neutrophils was significantly reduced in patients compared to controls. The levels of interleukin-2, interleukin-5, interleukin-8 and tumor necrosis factor alpha did not significantly differ between patients and controls. Flow cytometric analysis revealed that the integrin expression levels were reduced in lymphocytes (but not in neutrophils) obtained from systemic lupus erythematosus patients, while surface expression of the chemokine receptor 2 was similar in both neutrophils and lymphocytes.
Systemic lupus erythematosus patients receiving standard treatment presented with elevated systemic levels of interleukin-6 and interleukin-10, reduced neutrophil phagocytic capacity, and reduced lymphocyte expression of integrin even when symptoms were in remission. These alterations to innate immune components may put these individuals at a greater risk for acquiring infections.
比较接受标准治疗的系统性红斑狼疮患者与健康对照者的炎症特征。
在入组时从系统性红斑狼疮患者（n = 14）和对照者（n = 18）采集外周静脉血。血液样本用于通过流式细胞术定量检测中性粒细胞和淋巴细胞中CD11b（整合素）和趋化因子受体CXCR2表达的表面抗原，同时检测血清样本中的细胞因子。通过纯化的中性粒细胞吞噬人血浆调理的酵母聚糖的能力进行检测。
患者的疾病活动指数中位数（四分位间距）为1.0（0 - 2.0），具有缓解期患者的特征。与对照组相比，患者组血清白细胞介素 - 6和白细胞介素 - 10浓度显著更高，且与对照组相比，患者循环中性粒细胞的吞噬指数显著降低。患者与对照组之间白细胞介素 - 2、白细胞介素 - 5、白细胞介素 - 8和肿瘤坏死因子α水平无显著差异。流式细胞术分析显示，从系统性红斑狼疮患者获得的淋巴细胞（而非中性粒细胞）中整合素表达水平降低，而趋化因子受体2在中性粒细胞和淋巴细胞中的表面表达相似。
即使症状处于缓解期，接受标准治疗的系统性红斑狼疮患者仍表现出全身白细胞介素 - 6和白细胞介素 - 10水平升高、中性粒细胞吞噬能力降低以及淋巴细胞整合素表达降低。这些先天性免疫成分的改变可能使这些个体感染的风险更高。
